John Sakys Sells 1,223 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CFO John Sakys sold 1,223 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $101.27, for a total transaction of $123,853.21. Following the sale, the chief financial officer owned 16,538 shares of the company’s stock, valued at approximately $1,674,803.26. This represents a 6.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mesa Laboratories Stock Up 0.2%

NASDAQ MLAB opened at $95.10 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. Mesa Laboratories, Inc. has a 1 year low of $55.45 and a 1 year high of $113.99. The stock has a market capitalization of $524.95 million, a PE ratio of 79.25 and a beta of 0.94. The business’s 50-day moving average is $101.92 and its 200 day moving average is $90.74.

Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. The business had revenue of $63.72 million for the quarter, compared to the consensus estimate of $65.21 million. During the same quarter in the prior year, the company earned ($1.31) EPS.

Mesa Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 15th. Shareholders of record on Friday, May 29th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, May 29th. Mesa Laboratories’s payout ratio is presently 53.33%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of MLAB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Mesa Laboratories by 4.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock worth $364,000 after purchasing an additional 143 shares during the period. American Century Companies Inc. increased its stake in shares of Mesa Laboratories by 1.5% during the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock valued at $1,265,000 after purchasing an additional 194 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Mesa Laboratories by 30.9% during the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 243 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Mesa Laboratories by 5.9% during the fourth quarter. Deutsche Bank AG now owns 4,440 shares of the medical instruments supplier’s stock valued at $349,000 after purchasing an additional 248 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Mesa Laboratories by 5,366.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 322 shares in the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.